BioSpace News Archive

Glympse, a biotechnology company developing revolutionary technology to diagnose and monitor disease, announced that it will be presenting on the new liquid biopsy approach to its biosensor platform at the American Association for the Study of Liver Disease annual The Liver Meeting, being held virtually from Nov. 12-15, 2021.

Fabrinet, a leading provider of advanced optical packaging and precision optical, electro-mechanical and electronic manufacturing services to original equipment manufacturers of complex products, announced its financial results for its first fiscal quarter ended September 24, 2021.

Inhibrx, Inc., a biotechnology company with four clinical programs in development and an emerging pre-clinical pipeline, announced that the Company will be presenting at the Connective Tissue Oncology Society, or CTOS, 2021 Virtual Annual Meeting taking place November 10-13, 2021.

Nevro Corp., a global medical device company that provides innovative, evidence-based solutions for the treatment of chronic pain, announced that a Delaware jury found that Nevro infringed two Boston Scientific patents directed to ways of manufacturing spinal cord stimulation leads, which Nevro obtains from a third-party supplier.

GC Pharma announced that the European Medicines Agency granted orphan drug designation to Hunterase ICV ) for the treatment of mucopolysaccharidosis type II in the European Union.

Rhizen Pharma commences dosing in a phase I/Ib trial to evaluate its novel PARP inhibitor (RP12146) in patients with advanced cancers.

Centessa Pharmaceuticals plc today announced proof-of-mechanism data from the first three subjects dosed in the ongoing repeat dose Phase 1 Part B study of ZF874 in subjects carrying at least one Z-mutated alpha-1-antitrypsin allele (PiXZ).

Mind Medicine (MindMed) Inc. is pleased to announce that CEO Robert Barrow will be speaking at Web Summit, taking place on November 1-4, 2021 in Lisbon, Portugal .

Miravo Healthcare™ Announces Third Quarter 2021 Results Release Date and Conference Call Details

Immatics N.V. today announced that the company will provide an update on its ACTengine® IMA203 trial in a late-breaking oral presentation as well as an update on Immatics’ next-generation CD8ab TCR-T approach at the 36th Annual Meeting of the Society for Immunotherapy of Cancer’s (SITC).